Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
A Novo spokesperson said in a statement to Reuters that the new analysis "demonstrates for the first time the benefits of ...
Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...
The study found that the majority of people on Wegovy lost weight, on average 10% of their body weight, in the first 15 ...
Global spending on obesity medications totaled $24 billion last year, IQVIA estimated in its latest five-year outlook, and ...
Patients sometimes have to stop using GLP-1 medications like Ozempic and Wegovy and risk regaining lost weight.
Novo Nordisk, maker of the blockbuster drugs for diabetes and weight loss respectively, has a market capitalisation of ...